What do systematic reviews say?

Premature central line removal, defined as number of central venous catheters (CVC) removed in the trial as deemed by the author as the source of infection (premature central line removal) · neonates that require central line

Exit‐site infection · neonates that require central line

Overall autism features Not assessed · children and adolescents with a diagnosis of autism

General health and function Not assessed · children and adolescents with a diagnosis of autism

Adverse events resulting from DUS surveillance · people who underwent a lower limb revascularisation

All‐cause mortality · people who underwent a lower limb revascularisation

Functional walking ability · people who underwent a lower limb revascularisation

Clinical severity scales · people who underwent a lower limb revascularisation

Quality of life scores · people who underwent a lower limb revascularisation

Adverse events resulting from DUS surveillance · people who underwent a lower limb revascularisation

Functional walking ability · people who underwent a lower limb revascularisation

Clinical severity scales · people who underwent a lower limb revascularisation

Limb salvage · people who underwent a lower limb revascularisation

Flare‐ups or relapse (continuous) · people with inflammatory bowel disease

Flare‐ups/relapse (dichotomous; adults) · people with inflammatory bowel disease

Flare‐ups or relapse (continuous) · people with inflammatory bowel disease

Flare‐ups/relapse (dichotomous; adults) · people with inflammatory bowel disease

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk for apnea

Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants at risk for apnea

Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants at risk for apnea